Phase III clinical trials with darbepoetin: Implications for clinicians

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 3 SPEC. ISS., 2005, Pages 407-416

  Glaspy, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Chemotherapy; Darbepoetin

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG ANTIBODY; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY FAILURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; SOLID TUMOR;

EID: 15844417388     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.02.001     Document Type: Review

References (25)

1. J.W. Eschbach Current concepts of anemia management in chronic renal failure: Impact of NKF-DOQI Semin Nephrol 20 2000 320-329
2. G. Triolo C. Canavese S. Di Giulio Reasons for producing guidelines on anemia of chronic renal failure: Dialysis outcome quality initiative of the National Kidney Foundation Int J Artif Organs 21 1998 751-756
3. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure National Kidney Foundation-Dialysis Outcomes Quality Initiative Am J Kidney Dis 30 1997 S192-S240
4. I.C. Macdougall R.D. Hutton I. Cavill G.A. Coles J.D. Williams Treating renal anaemia with recombinant human erythropoietin: Practical guidelines and a clinical algorithm BMJ 300 1990 655-659
5. J.W. Eschbach J.W. Adamson Guidelines for recombinant human erythropoietin therapy Am J Kidney Dis 14 1989 2-8
6. L.T. Goodnough K.C. Anderson S. Kurtz et al. Indications and guidelines for the use of hematopoietic growth factors Transfusion 33 1993 944-959
7. G.F. Strippoli C. Manno F.P. Schena J.C. Craig Haemoglobin and haematocrit targets for the anaemia of chronic renal disease Cochrane Database Syst Rev 2003 CD003967
8. J. Crawford D. Cella C.S. Cleeland et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888-895
9. S.D. Ross K. Fahrbach D. Frame et al. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review Clin Ther 25 2003 1786-1805
10. A.C. Heatherington J. Schuller A.J. Mercer Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report Br J Cancer 84 supplement 1 2001 11-16
11. J.A. Glaspy N.S. Tchekmedyian Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy Oncology (Huntingt) 16 2002 23-29
12. J. Vansteenkiste E. Poulsen G. Rossi J. Glaspy Darbepoetin alfa: Impact on treatment for chemotherapy-induced anemia and considerations in special populations Oncology (Huntingt) 16 2002 45-55
13. D.L. Fairclough D.D. Gagnon M.J. Zagari et al. Evaluation of quality of life in a clinical trial with nonrandom dropout: The effect of epoetin alfa in anemic cancer patients Qual Life Res 12 2003 1013-1027
14. D. Kotasek G. Steger W. Faught et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study Eur J Cancer 39 2003 2026-2034
15. J.A. Glaspy J.S. Jadeja G. Justice et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Br J Cancer 87 2002 268-276
16. J.A. Glaspy J.S. Jadeja G. Justice et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease Cancer 97 2003 1312-1320
17. S. Vadhan-Raj F. Schreiber L.C. Thomas et al. Every-2-week darbepoetin alfa improves fatigue and energy rating scores in cancer patients (pts) undergoing chemotherapy Proc Am Soc Clin Oncol 22:732 abstr 2003
18. S. Vadhan-Raj B. Mirtsching V. Charu et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks J Support Oncol 1 2003 131-138
19. R.E. Smith Jr N.S. Tchekmedyian D. Chan et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer Br J Cancer 88 2003 1851-1858
20. J. Vansteenkiste D. Tomita G. Rossi R. Pirker Darbepoetin alfa in lung cancer patients on chemotherapy: A retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline Support Care Cancer 2004
21. T.J. Littlewood J. Nortier B. Rapoport et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy Hematol Oncol 21 2003 169-180
22. M. Hedenus S. Hansen K. Taylor et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies Br J Haematol 119 2002 79-86
23. J. Glaspy J.S. Jadeja G. Justice et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy Br J Cancer 84 supplement 1 2001 17-23
24. J.A. Glaspy Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency Oncology (Huntingt) 16 2002 71-77
25. M. Auerbach H. Ballard J.R. Trout et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial J Clin Oncol 22 2004 1301-1307